MedTrace Logo

Nepal Undifferentiated Febrile Illness Trial

NCT02773407 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2023-12-06

No results posted yet for this study

Summary

The purpose of the study is to determine whether azithromycin or cotrimoxazole is the best empirical treatment for undifferentiated febrile illness in Nepal

Conditions

  • Undifferentiated Febrile Illness

Interventions

DRUG

Azithromycin

DRUG

Co-trimoxazole

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • Oxford University Clinical Research Unit, Vietnam

    lead OTHER

Principal Investigators

  • Buddha Basnyat, MBBS,MSc,MD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2019-08-04
Completion
2019-08-04

Countries

  • Nepal

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02773407 on ClinicalTrials.gov